Figure 2.

Blautia bacteria could predict the effect of AZA therapy in patients with inflammatory bowel disease (IBD)

(A) Flow chart in cohort 1 of Renji hospital.

(B) LDA effect size analysis in the fecal samples of patients with IBD in NR (n = 22) and in R (n = 27) after performing 16S DNA sequencing.

(C) The amount of B. wexlerae/B. luti species in the feces of patients with IBD in cohort 1. Significance was determined using a non-parametric Wilcoxon rank-sum test (R, n = 27; NR, n = 22).

(D and E) The amount of B. wexlerae/B. luti species was significantly increased in the feces of NR group (D, R, n = 57; NR, n = 34), both in patients with ulcerative colitis (UC; R, n = 21; NR, n = 11) and patients with Crohn’s disease (CD; R, n = 36; NR, n = 23) (E). Non-parametric Wilcoxon rank-sum test.

(F) Classification performance of multivariable logistic regression model using relative abundance of B. wexlerae/B. luti was assessed by area under the receiver operating characteristic (ROC) in cohort 2 (R: n = 57, NR: n = 34, AUC: 77.22%, 95% confidence interval [CI]: 67.32%–87.12%), respectively.

(G) Analysis of the flare-free survival in patients with high (n = 41) versus low (n = 50) B. wexlerae/B. luti abundance in cohort 2.

(H) Multivariable analysis was performed in cohort 2. The bars correspond to 95% CIs.